Skip to main content
. 2024 Apr 16;14:8804. doi: 10.1038/s41598-024-59311-0

Table 3.

The ablation study.

Modalities Overall N (%) SVEB (%) VEB (%) F (%)
Acc Se PPV F1 Se PPV F1 Se PPV F1 Se PPV F1
CA 99.3 99.5 99.8 99.6 96.4 91.6 93.9 98.6 98.4 98.5 89.4 80.9 84.9
SE 99.4 99.6 99.8 99.7 96.2 93.4 94.8 98.7 97.3 98.0 87.6 86.0 86.8
CBAM 99.3 99.6 99.8 99.7 96.6 93.1 94.8 98.6 98.0 98.3 88.8 82.2 85.4
Without Fca_1 99.1 99.7 99.5 99.6 89.4 95.8 92.5 97.8 96.8 97.3 79.5 82.6 81.0
Without Fca_2 99.2 99.8 99.5 99.6 89.9 96.0 92.8 98.1 97.2 97.6 73.3 92.9 81.9
Change number of ResBlock[1,1,1,1] 99.2 99.7 99.6 99.6 90.1 96.4 93.1 98.6 96.6 97.6 77.0 89.9 83.0
Focal_Loss 99.1 99.7 99.6 99.6 89.6 96.9 93.1 98.4 96.2 97.3 79.5 82.6 81.0
RP only 99.2 99.8 99.5 99.6 89.6 96.5 92.9 98.5 97.4 97.9 78.9 90.7 84.4
GAF only 99.1 99.7 99.5 99.6 89.9 95.1 92.4 97.8 96.5 97.1 80.7 89.0 84.6
MTF only 98.8 99.7 99.2 99.4 85.8 96.0 90.6 95.2 95.9 95.5 76.4 84.2 80.1
Proposed 99.6 99.9 99.9 99.9 98.0 96.6 97.3 99.1 98.9 99.0 90.7 94.2 92.4

Significant values are in bold.